Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis

The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PM...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-05, Vol.14 (9), p.2331
Main Authors: García-Fortes, María, Hernández-Boluda, Juan C, Álvarez-Larrán, Alberto, Raya, José M, Angona, Anna, Estrada, Natalia, Fox, Laura, Cuevas, Beatriz, García-Hernández, María C, Gómez-Casares, María Teresa, Ferrer-Marín, Francisca, Saavedra, Silvana, Cervantes, Francisco, García-Delgado, Regina, On Behalf Of The Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas Gemfin
Format: Article
Language:English
Subjects:
Age
Chronic illnesses
Clinical medicine
Coexistence
Comorbidity
Diabetes
Diabetes mellitus
Dyslipidemia
Hematological diseases
Hepatitis C
Hypertension
Leukemia
Lung diseases
Medical prognosis
Mortality
Multivariate analysis
Mutation
Myelofibrosis
Patients
Polycythemia
Polycythemia vera
Renal function
Risk factors
Smoking
Survival
Tumors
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4.96, p < 0.001), smoking (HR = 5.08, p < 0.001), dyslipidemia (HR = 4.65, p < 0.001) and hepatitis C virus (HCV) (HR = 4.26, p = 0.015) were most adversely associated with OS. Diabetes (HR = 3.01, p < 0.001), pulmonary disease (HR = 3.13, p < 0.001) and renal dysfunction (HR = 1.82, p = 0.037) were also associated with an increased risk of death. Multivariate analysis showed that pulmonary disease (HR = 2.69, p = 0.001), smoking (HR = 3.34, p < 0.001), renal dysfunction (HR = 2.08, p = 0.043) and HCV (HR = 11.49, p = 0.001) had a negative impact on OS. When ruxolitinib exposure was included in the model, the effect of each comorbidity on survival was modified. Therefore, individual comorbidities should be taken into account in determining the survival prognosis for patients with MF.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14092331